/* Story-stimulus data, NOTCH FRAME (mechanism-anchored).
   Verbatim from uploads/story_stimulus_v1_notch_frame.md.
   Item convention used by the renderer in page-prebio-stimulus.jsx:
     leading "★ "  → curated (starred) bullet
     leading "» "  → group sub-label (always visible, never filtered)
     otherwise     → ordinary bullet
   Inline **bold** and *italic* are converted at render time. */

const NOTCH_POSTURE = {
  label: "What this version is",
  paras: [
    `The **mechanism-anchored** positioning. The story leads with what makes ProTGen scientifically distinct: **targeted Notch activation as the upstream control point for restoring immune competence.** The platform thesis is the protagonist; the indications are the proof the protagonist works.`,
    `**Posture toward the strategic axis.** *"We are the only clinical-stage, platform-grade lever on the organ that decides whether you can rebuild your immune system."*`,
    `**Where this lands hardest.** Sophisticated biotech investors who underwrite mechanism. Pharma BD scouts looking for upstream control points to fill portfolio gaps. Cell-therapy specialists who already know what Notch is. Scientific recruits who want to work on a hard problem with translational consequences. Clinical investigators who want a serious biological rationale.`,
    `**Where this risks losing.** Longevity-investor audiences that want outcome-shaped language. General-press or non-specialist readers who bounce off "Notch." The warm-intro forwarded-PDF reader who has 60 seconds and doesn't know the vocabulary.`,
    `**How to use this artifact.** Read past anything that doesn't land. Circle anything you'd actually say at a BIO booth. Tell us what's missing.`,
  ],
};

const NOTCH_STIM = [
  /* 1 */ { quote: `Notch is the body's switch for building immune competence. We learned to turn it back on, with precision.` },
  /* 2 */ { items: [
    `★ "The signal that built you can rebuild you."`,
    `★ "Notch was the architect. Now it's the renovator."`,
    `"Off-switch found. On-switch built. We're the wiring in between."`,
    `"One signal. One organ. A different shape of aging."`,
    `"Targeted, not flooded. That's the whole story."`,
    `★ "We don't reverse aging. We restart the factory."`,
    `"Same body. Same biology. Different conductor."`,
  ] },
  /* 3 */ { items: [
    `★ A dimmer switch, not an on/off switch, targeted activation as control, not flood.`,
    `A reopened factory door at the back of a building everyone forgot was there.`,
    `A keychain being refilled, keys at 20 vs. keys at 70, with the count restoring.`,
    `★ A foreman returning to a factory line that had been running on memory.`,
    `The light coming back on in one specific room of a dark house.`,
    `A conductor stepping back onto an empty podium while the orchestra waits.`,
  ] },
  /* 4 */ { items: [
    `★ "Notch = undruggable / dangerous / pleiotropic" → reframe to *"Notch* was *undruggable. Targeted activation changes the safety calculus."*`,
    `★ "Longevity = vibes-and-supplements with biology spray-paint" → reframe to *"ProTGen has a clinical asset, an IND path, and a manufacturing partner. That's not longevity in the loose sense. It's medicine."*`,
    `"Thymus = something I haven't thought about since high school biology" → use it. The forgotten organ is a feature. The room learns the word fresh from us.`,
    `★ "Platform companies = vague, broad, hard to underwrite" → reframe to *"the platform has a first product, in IND-readying. The platform isn't speculation, it's what the product proves."*`,
    `"Immune restoration = post-transplant supportive care" → reframe to *"immune restoration is the upstream of post-transplant survival, vaccine response, and age-related infection mortality. The supportive-care framing was the only framing because there was no instrument. Now there is one."*`,
  ] },
  /* 5 */ { items: [
    `★ **"GPS for the immune system."** Notch as the navigation signal that tells stem cells which destination (T-cell lineage) to head toward.`,
    `★ **"Yamanaka for the thymus."** Cellular reprogramming rewinds cell identity. ProTGen rewinds organ output.`,
    `**"Tuning fork for hematopoiesis."** The precise resonance that drives the system back into harmony.`,
    `**"Thermostat for immune output."** Turn the system back on, set the level.`,
    `**"The control room behind the immune system."** Every other immune therapy works at the operator level. ProTGen works at the controls.`,
    `★ **"Notch-as-conductor for the immune orchestra."** Every player needs the conductor's cue to play in time.`,
    `**"The GLP-1 of the immune system."** Carter's own phrase, drug class that became massive because it hit an upstream lever everyone underestimated.`,
  ] },
  /* 6 */ { items: [
    `**The factory and the foreman.** The thymus is a factory. Its foreman (Notch signaling) retired in your 20s. The line keeps running on old workers. Eventually the orders pile up. ProTGen reopens the foreman's office.`,
    `★ **The dimmer, not the switch.** Pan-Notch agonists were the light switch, too much, too dangerous. Targeted Notch activation is the dimmer, precise, controllable, safe.`,
    `**The receptionist at the stem-cell building.** Without Notch, the right cells never get the memo to become T-cells. ProTGen is making sure the receptionist shows up to work.`,
    `★ **The signal at the right intersection.** Hematopoiesis is a network of streets. Notch is the traffic signal at the intersection that decides "T-cell destination this way." That signal was broken. We rebuilt it.`,
    `**The conductor and the orchestra.** Every immune cell is a musician. The conductor (Notch) signals when to play. The conductor stopped showing up. We're putting the conductor back on the podium.`,
  ] },
  /* 7 */ { items: [
    `★ "Most longevity bets are upstream of every organ. Most immune bets are downstream of every cell. We're in the layer in between, the signal layer, where neither the geneticists nor the biologists have a clinical asset."`,
    `★ "Your thymus shut down on a clock in your 20s. No one told you, because no one had anything to do about it. We do."`,
    `"Every CAR-T patient pharma has paid billions to save is now living with the immune system that survived the treatment. None of those patients have a therapy for the next problem."`,
    `★ "Notch was the most famous undruggable target in immunology, for the same reason a thermostat is undruggable if you can only break it or weld it. We built the dial."`,
    `"Cellular reprogramming raised five billion dollars to address upstream aging. The organ that gates immune aging is the thymus. The thymus has one clinical-stage company. That company is ProTGen."`,
    `"There is no longevity therapy currently in clinical trials that addresses the organ most responsible for immune aging. Until ProT-096."`,
  ] },
  /* 8 */ { items: [
    `★ "Why did evolution build a switch that turns off the immune system's factory in early adulthood?"`,
    `"What's the difference between a 90-year-old who recovers like a 50-year-old and one who gets pneumonia from a paper cut?"`,
    `"Why does a CAR-T patient sometimes live for years after their cancer is gone, but die of an infection that wouldn't have touched them at 30?"`,
    `★ "What single organ in your body operates on a shutdown timer you can't feel?"`,
    `"Why has every longevity company found something to say about cells, but nothing to say about the one organ that decides your immune age?"`,
  ] },
  /* 9 */ { items: [
    `★ "Everyone knows the immune system weakens with age. Almost no one knows it's because one specific organ shuts down on a schedule. Almost no one knows that schedule is reversible in principle."`,
    `"Everyone knows what CAR-T is. Almost no one talks about what happens to the immune system that took the CAR-T."`,
    `"Everyone has heard the word 'thymus.' Almost no one could draw it on an anatomy chart."`,
    `★ "Investors fund longevity. Investors fund immune therapeutics. The gap between them, where the thymus lives, has almost no one in it."`,
    `"Pharma BD scouts age-related disease. Pharma BD scouts immune therapies. The intersection has had nothing to scout for."`,
  ] },
  /* 10 */ { items: [
    `"The single switch that explains why old people get sick, and one company found the dial."`,
    `★ "Why your thymus retired before you turned 30, and the company learning to rehire it."`,
    `"Pharma will spend $80 billion on immune-aging in the next decade. The acquisition list has fewer than 20 names."`,
    `★ "The longevity company that doesn't sell longevity, and why investors are paying attention."`,
    `"The mechanism cellular reprogramming forgot, and the team building the clinical-stage answer."`,
  ] },
  /* 11 */ { items: [
    `★ **The forgotten foreman.** Once there was a factory whose foreman left early one morning and never came back. The line kept running for years on the workers who were already trained. New orders came in, but no new workers were trained for them. The factory began to fall behind. The foreman's office sat empty. One day a small team learned how to bring the foreman back. The factory began to keep up again. Not by adding workers, by training new ones.`,
    `**The lighthouse keeper.** Every coastal village depends on a lighthouse. As long as the keeper shows up at dusk, ships find their way home. When the keeper stops showing up, ships still come, but more of them run aground. The keeper isn't responsible for the ships. The keeper is responsible for the signal that lets the ships do their job.`,
    `★ **The keychain.** At 20 you carry a keychain with a million different keys for the locks viruses use. At 70 you carry a few thousand. The locks didn't change. The keychain shrunk. We're restocking the keychain.`,
    `**The conductor's empty podium.** A symphony with the world's best musicians but no conductor will still make noise. It won't make music.`,
  ] },
  /* 12 */ { items: [
    `★ "Notch is the receptionist at the gate of the stem-cell building. Without her, nobody gets the memo to become a T-cell."`,
    `"The thymus is not 'an organ' the way the liver is. It's a school. Children (immature cells) walk in, get educated (selected, trained), walk out as defenders. By age 70 the school has 95% fewer classrooms."`,
    `★ "Restoring immune competence is not 'rejuvenation.' It is *re-staffing the school* in a body that already knows it needs the staff back."`,
    `"ProT-096 is what you give the cancer patient whose immune system was rebooted by treatment. The reboot worked. The operating system didn't reload. We're the OS install."`,
  ] },
  /* 13 */ { items: [
    `**The hip-fracture patient in their 80s vs. their 30s.** Same fracture, same hospital, vastly different recovery curves. Most of the gap is immune competence.`,
    `★ **The CAR-T survivor at year five.** Cancer-free. Living with the immune system that survived ablative chemotherapy. Repertoire collapsed. Vaccine response blunted. Living between treatments that didn't quite finish the job.`,
    `**The 78-year-old with their grandchildren in flu season.** Cared for, cautious, trying to be present. Their immune system is the only thing standing between "Thanksgiving with family" and "weeks of pneumonia."`,
    `★ **The post-HSCT patient at year two.** Saved by the transplant. Lost the immune system the transplant relied on. Living with infection prophylaxis as a fact of life.`,
  ] },
  /* 14 */ { items: [
    `★ **Frank, 78.** Hip fracture in his garden. With current standard-of-care: six months of antibiotics, three readmissions, eventually assisted living. With restored immune competence: home in three weeks, back in the garden by spring.`,
    `**Marie, 65, lymphoma survivor at year four.** Cancer-free. Still on monthly IVIG. Her immune system kept her alive long enough to survive cancer. Now nobody is rebuilding it.`,
    `★ **Carter and the operating team.** Carter's whole career has been at the cell-therapy frontier. The team has shipped clinical assets at Cellares partners before. The platform isn't a thesis, it's what these people do for a living.`,
    `**The unnamed researcher** who first realized the Notch off-switch wasn't actually broken. It was just waiting for the right key.`,
  ] },
  /* 15 */ { items: [
    `★ "Targeted, not flooded."`,
    `★ "The factory's foreman retired in your 20s."`,
    `"The keychain shrinks by 99 percent."`,
    `"The off-switch we found out we could turn back on."`,
    `★ "One signal. One organ. A different shape of aging."`,
    `"We don't reverse aging. We restock the immune system."`,
    `"Notch was the famous undruggable target. We built the dial."`,
  ] },
  /* 16 */ { items: [
    `Everyone has watched someone they love get old. Everyone has seen the difference between *getting older* and *getting frail*. The difference is recoverability. Recoverability is immune.`,
    `★ Every investor with a position in immune therapeutics has felt the question of what happens *after* the CAR-T works. Most have not seen a credible answer.`,
    `Every pharma BD person looking at age-related disease has noticed that the immune-aging window is structurally empty of clinical-stage assets.`,
    `★ Every clinical investigator who works with cancer survivors knows the story doesn't end at "cancer-free." It ends at "still alive at year 10."`,
  ] },
  /* 17 */ { items: [
    `**Authority.** The Nobel-grade lineage of Notch biology (Artavanis-Tsakonas; Spradling). Cellares as a marquee partner. ARMI as the regional translational anchor. Clinical investigators who already work with refractory hematologic malignancy patients.`,
    `★ **Counter-authority.** Most of the people who said Notch was undruggable are still saying it. Their argument is structurally about pan-agonism. Targeted activation is a different conversation they haven't had yet.`,
    `**Insider absence.** No senescence company has a thymic-restoration program. No major pharma has an internal Notch-activator platform. The space's emptiness is its own form of evidence.`,
  ] },
  /* 18 */ { items: [
    `★ **Cellares automation** reduces manual touchpoints, raises reproducibility, protects comparability. The de-risk on the operational layer that has historically been where good cell-therapy stalls.`,
    `**Targeted, not pan-agonist.** The chemistry is built to engage specific Notch family members. The safety calculus rests on this.`,
    `★ **Patient-personalized.** ProT-096's progenitor T-cells are derived from the patient's own stem cells. The immune-tolerance question is structurally addressed.`,
    `**Thymic-output biomarkers.** Early clinical work measures something nobody has had a tool to move before.`,
    `**IND-readying is on a concrete clock**, not "in development."`,
  ] },
  /* 19 */ { items: [
    `★ "Your thymus makes 1,000 times fewer T cells at 70 than at 20. That's the same factor as the difference between a single house and a small city. We are rebuilding the city."`,
    `"By 60, your thymus is 5 percent of the size it was at 20. Your kidney isn't 5 percent. Your liver isn't. Your heart isn't. The thymus is the only major organ that shrinks by 95 percent on schedule. That's not aging. That's a targeted shutdown."`,
    `★ "By 80 you have 10 percent of the T-cell receptors you had at 20. We are the only company we know of with a clinical-stage way to rebuild that count."`,
    `"Every year, 100 million people receive an immune system 'tune-up' through vaccines. None work as well at 70 as they did at 30, because the factory has already gone offline."`,
    `"Pharma spent $40 billion-plus acquiring CAR-T programs over the last decade. The CAR-T patients they bought are now the ones dying of opportunistic infection."`,
  ] },
  /* 20 */ { items: [
    `★ "If targeted Notch activation can rebuild immune competence in patients whose immune systems were destroyed by ablative chemotherapy and stem-cell transplantation, the most damaged immune systems in medicine, almost any milder failure mode is downstream of the same lever."`,
    `"If we can produce ProT-096 reproducibly with Cellares automation in a personalized cell-therapy modality, the most operationally demanding cell-therapy class, the manufacturing scaffold for the rest of the platform is built."`,
    `★ "If we can pass IND review for a personalized progenitor T-cell therapy in refractory hematologic malignancy, the highest-bar clinical entry, the regulatory chassis for adjacent indications is essentially in place."`,
  ] },
  /* 21 */ { items: [
    `Cellares manufacturing run data on the first clinical cohort.`,
    `★ IND submission package as evidence of execution discipline.`,
    `Thymic-biomarker readouts from early clinical work.`,
    `Published Notch biology, the team's prior peer-reviewed work and the chemistry's published derivation.`,
    `★ Plant tour of the Cellares facility for serious partnership-track diligence.`,
  ] },
  /* 22 */ { items: [
    `★ "The team is real. The asset is real. The mechanism is real. The category is empty. We are early to something that will not be empty for long."`,
    `"There is a version of medicine in which every cancer survivor gets a Notch-activator regimen as standard post-treatment care, and hip-fracture mortality in the over-75 population drops by 40 percent. We're working on that version."`,
    `★ "Most longevity stories ask the audience to believe in something abstract. We ask them to believe in a clinical asset for refractory leukemia patients. Everything else is downstream of that."`,
  ] },
  /* 23 */ { items: [
    `★ "If I look at Frank, 78, home from the hospital in three weeks playing catch with his great-grandkid in May, I will act. If I look at the 5 million older Americans who will fracture a hip this decade, I freeze."`,
    `"If I look at Marie, 65, on her fourth year cancer-free but stepping off the maintenance protocol because her immune system rebuilt itself, I act."`,
    `★ "Show me the patient. Don't show me the population. The story is the patient whose life looks different because the immune system did."`,
  ] },
  /* 24 */ { items: [
    `» For the investor / pharma BD audience, underneath the visible asks.`,
    `Being early to a category that becomes obvious.`,
    `★ Being right about a thesis nobody else was ready to back.`,
    `Getting the platform before competitors realize a category exists.`,
    `★ Having clinical-stage discipline backing a platform-grade thesis.`,
    `Underwriting at clinical-stage today, exiting at category-defining tomorrow.`,
    `» For clinical-investigator / patient-care audiences.`,
    `A real answer for patients whose immune systems are the gap between recovery and decline.`,
    `★ A treatment that addresses the cause, not the symptoms.`,
    `A way to extend the work the rest of medicine has already done.`,
  ] },
  /* 25 */ { items: [
    `★ Replace **"longevity"** with **"immune-system age."**`,
    `★ Replace **"rejuvenation"** with **"restoration."**`,
    `Replace **"platform"** with **"control point."**`,
    `Replace **"broad"** with **"many indications downstream of one mechanism."**`,
    `★ Replace **"anti-aging"** with **"immune-restoration medicine."**`,
  ] },
  /* 26 */ { items: [
    `For longevity investors: *"the bet that makes you the early-backer story when the category becomes obvious."*`,
    `★ For pharma BD: *"the platform you partner with before your competitors recognize the category."*`,
    `For clinical investigators: *"the first trial that actually moves the upstream lever you've been studying for decades."*`,
    `★ For scientific recruits: *"the chance to work on the organ that decides whether the rest of medicine can save the patient."*`,
  ] },
  /* 27 */ { items: [
    `★ Sophisticated investor: *"I'm someone who backs mechanism-first, not vibes-first."*`,
    `★ Pharma BD: *"I'm someone who finds the next portfolio category before consensus forms."*`,
    `Clinical investigator: *"I'm someone who picked the field that needed a clinical-stage instrument and used it to change the practice."*`,
    `Scientific recruit: *"I'm someone who works on hard problems with real translational consequences."*`,
  ] },
  /* 28 */ { items: [
    `★ A pharma BD director who saw the Notch-activator concept three years ago, passed because "undruggable," and now watches a competitor sign a partnership at materially worse terms. The story isn't the company we're competing with. The story is the BD director who gets the call from her CEO asking why she passed.`,
    `An investor who underwrote ProT-096 at clinical-stage and watched the platform expand around it. Three years later, the second asset closes. Five years later, a strategic acquires.`,
    `★ A clinical investigator who built the trial that produced the first measurable thymic-restoration readout. The data spawned five investigator-initiated follow-up trials. Her career rotated around the fact that the right instrument arrived at the right time.`,
  ] },
  /* 29 */ { items: [
    `★ "Imagine ProTGen ten years from now. Every CAR-T patient gets a Notch-activator regimen as standard post-treatment care. Hip-fracture mortality in the over-75 population is down 40 percent. Vaccine non-response in the elderly is solved. The platform has eight more indications in pipeline. The acquisition happened three years ago at category-defining terms."`,
    `"Imagine the BIO floor five years from now. Every longevity panel includes the question 'what are you doing on the thymus?' The companies that don't have an answer feel suddenly thin. The first company to put a clinical-stage asset there set the entire conversation."`,
    `★ "Imagine the venture portfolio that has 'restoring immune competence' as a thesis line. Today, that line is mostly empty. Five years from now, every fund worth its salt has an answer. Today's lead investors will name themselves having been first."`,
  ] },
  /* 30 */ { items: [
    `★ "If you had to name the one organ that's the difference between healthy aging and frail aging, which would it be? Most people get it wrong."`,
    `★ "When did the immune system you were born with stop showing up to work for you?"`,
    `"If I told you there's an organ in your body that retired before you turned 30, and nobody's been able to bring it back, would you want to meet the company that just did?"`,
    `"What if everything you thought you knew about why old people get sick had the wrong subject?"`,
    `★ "What's the upstream lever for every immune therapy currently in the market?"`,
    `"If the next $80 billion in pharma immune-aging spend has to come from somewhere, where does it come from?"`,
    `"What would your portfolio look like if 'restoring immune competence' was a thesis line?"`,
  ] },
  /* 31 */ { items: [
    `★ "Your thymus, the organ that makes your immune system's adaptive defenders, produces 1,000 times fewer cells at 70 than at 20. By any other measure, that's not aging, that's organ failure."`,
    `"Every year, 100 million people get vaccines. None of those vaccines work as well at 70 as they did at 30, because the factory making the responders has already gone offline."`,
    `★ "The reason chemotherapy survivors die of pneumonia five years later isn't the cancer. It's that nobody rebuilt their immune system after we destroyed it."`,
    `"Bone-marrow transplants save lives. Half of those saved lives are lost to infection in the following decade, not from the transplant, but from the immune system that never came back."`,
    `"Cellular reprogramming has raised $5 billion. Notch-activator immune restoration has raised about $20 million. The mechanism gap doesn't justify the funding gap."`,
    `★ "Pharma will spend an estimated $80 billion on immune-aging in the next decade. The acquisition list has fewer than 20 companies on it."`,
  ] },
  /* 32 */ { items: [
    `★ "What's the longevity company you could underwrite the way you underwrite an oncology asset, clinical pipeline, ICD-10 code on day one, pharma BD pull?"`,
    `"If immune-aging is the upstream of everything we call 'aging,' why is the entire longevity-investment thesis focused downstream of it?"`,
    `★ "When was the last time you funded a control-point platform with a near-term clinical wedge AND a 30-year category horizon?"`,
    `"What's the difference between 'we're working on aging' and 'we're working on the one organ that gates aging'?"`,
    `"Where's the longevity company that's actually upstream of every other longevity bet?"`,
    `★ "How many companies in your pipeline file an IND on a personalized progenitor T-cell therapy with automated manufacturing?"`,
    `"What's the asset you can underwrite at clinical-stage today and platform-stage in 36 months?"`,
  ] },
  /* 33 */ { items: [
    `★ "There are more immune-compromised cancer survivors in America today than there are people newly diagnosed with diabetes each year. None of them have a therapy for what's killing them."`,
    `"Cellular reprogramming has raised $5 billion over the last five years. Notch-activator immune restoration has raised about $20 million. The mechanism gap doesn't justify the funding gap."`,
    `★ "Of the top 12 longevity companies by capital raised, eight have no INDs filed. Two have IND-cleared programs in non-immune indications. One has a clinical asset in immune restoration. That one is ProTGen."`,
    `"Pharma spent $40 billion-plus acquiring CAR-T programs over the last decade. The CAR-T patients they bought are now the ones dying of opportunistic infection. The next $40 billion wave is whoever rebuilds them."`,
    `★ "The market opportunity for restoring immune competence in cancer survivors alone is $30 billion annually. That's the FIRST indication. The platform addresses six more."`,
    `"Every clinical-stage longevity bet currently in funding works upstream of immune aging. The thymus is the upstream of immune aging. ProTGen is the only company we know of with a clinical asset there."`,
  ] },
];

Object.assign(window, { NOTCH_POSTURE, NOTCH_STIM });